CoChat

Novel and optimized strategies for inducing fibrosis in vivo: focus on Duchenne Muscular Dystrophy

Open access
Pessina, Patrizia, Cabrera, Daniel, Morales, María Gabriela, Riquelme, Cecilia A, Gutiérrez, Jaime, Serrano, Antonio L, Brandan, Enrique, Muñoz-Cánoves, Pura · 2014 · Skeletal Muscle
Cited by 100

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Fibrosis, an excessive collagen accumulation, results in scar formation, impairing function of vital organs and tissues. Fibrosis is a hallmark of muscular dystrophies, including the lethal Duchenne muscular dystrophy (DMD), which remains incurable. Substitution of muscle by fibrotic tissue also complicates gene/cell therapies for DMD. Yet, no optimal models to study muscle fibrosis are available. In the widely used mdx mouse model for DMD, extensive fibrosis develops in the diaphragm only at advanced adulthood, and at about two years of age in the 'easy-to-access' limb muscles, thus precluding fibrosis research and the testing of novel therapies. METHODS: We developed distinct experimental strategies, ranging from chronic exercise to increasing muscle damage on limb muscles of young mdx mice, by myotoxin injection, surgically induced trauma (laceration or denervation) or intramuscular delivery of profibrotic growth factors (such as TGFβ). We also extended these approaches to muscle of normal non-dystrophic mice. RESULTS: These strategies resulted in advanced and enhanced muscle fibrosis in young mdx mice, which persisted over time, and correlated with reduced muscle force, thus mimicking the severe DMD phenotype. Furthermore, increased fibrosis was also obtained by combining these procedures in muscles of normal mice, mirroring aberrant repair after severe trauma. CONCLUSIONS: We have developed new and improved experimental strategies to accelerate and enhance muscle fibrosis in vivo. These strategies will allow rapidly assessing fibrosis in the easily accessible limb muscles of young mdx mice, without necessarily having to use old animals. The extension of these fibrogenic regimes to the muscle of non-dystrophic wild-type mice will allow fibrosis assessment in a wide array of pre-existing transgenic mouse lines, which in turn will facilitate understanding the mechanisms of fibrogenesis. These strategies should improve our ability to combat fibrosis-driven dystrophy progression and aberrant regeneration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/2044-5040-4-7

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 38

  1. Briggs D, Morgan JE: Recent progress in satellite cell/myoblast engraftment - relevance for therapy. FEBS J. 2013, 280: 4281-4293. · DOI
  2. Yablonka-Reuveni Z, Anderson JE: Satellite cells from dystrophic (mdx) mice display accelerated differentiation in primary cultures and in isolated myofibers. Dev Dynamics. 2006, 235: 203-212. · DOI · Paper page
  3. Grounds MD, Shavlakadze T: Growing muscle has different sarcolemmal properties from adult muscle: a proposal with scientific and clinical implications: reasons to reassess skeletal muscle molecular dynamics, cellular responses and suitability of experimental models of muscle disorders. Bio Essays. 2011, 33: 458-468.
  4. Muntoni F: Cardiac complications of childhood myopathies. J Child Neurol. 2003, 18: 191-202. · DOI
  5. Benedetti S, Hoshiya H, Tedesco FS: Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies. FEBS J. 2013, 280: 4263-4280. · DOI
  6. Tedesco FS, Hoshiya H, D’Antona G, Gerli MF, Messina G, Antonini S, Tonlorenzi R, Benedetti S, Berghella L, Torrente Y, Kazuki Y, Bottinelli R, Oshimura M, Cossu G: Stem cell-mediated transfer of a human artificial chromosome ameliorates muscular dystrophy. Sci Trans Med. 2011, 3: 96ra78- · DOI · Paper page
  7. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ: The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 1989, 244: 1578-1580. · DOI · Paper page
  8. Carnwath JW, Shotton DM: Muscular dystrophy in the mdx mouse: histopathology of the soleus and extensor digitorum longus muscles. J Neuro Sci. 1987, 80: 39-54. · DOI · Paper page
  9. Ardite E, Perdiguero E, Vidal B, Gutarra S, Serrano AL, Munoz-Canoves P: PAI-1-regulated miR-21 defines a novel age-associated fibrogenic pathway in muscular dystrophy. J Cell Biol. 2012, 196: 163-175. · DOI
  10. Menetrey J, Kasemkijwattana C, Fu FH, Moreland MS, Huard J: Suturing versus immobilization of a muscle laceration. A morphological and functional study in a mouse model. Am J Sports Med. 1999, 27: 222-229. · DOI · Paper page
  11. Serrano AL, Murgia M, Pallafacchina G, Calabria E, Coniglio P, Lomo T, Schiaffino S: Calcineurin controls nerve activity-dependent specification of slow skeletal muscle fibers but not muscle growth. Proc Natl Acad Sci USA. 2001, 98: 13108-13113. · DOI · Paper page
  12. Morales MG, Cabello-Verrugio C, Santander C, Cabrera D, Goldschmeding R, Brandan E: CTGF/CCN-2 over-expression can directly induce features of skeletal muscle dystrophy. J Pathol. 2011, 225: 490-501. · DOI · Paper page
  13. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A: Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012, 9: 676-682. · DOI · Paper page
  14. Cabello-Verrugio C, Morales MG, Cabrera D, Vio CP, Brandan E: Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles. J Cellular Mol Med. 2012, 16: 752-764. · DOI · Paper page
  15. Biernacka A, Frangogiannis NG: Aging and cardiac fibrosis. Aging Dis. 2011, 2: 158-173.
  16. Brandan E, Gutierrez J: Role of proteoglycans in the regulation of the skeletal muscle fibrotic response. FEBS J. 2013, 280: 4109-4117. · DOI
  17. MacDonald EM, Cohn RD: TGFbeta signaling: its role in fibrosis formation and myopathies. Cur Opinion Rheumatol. 2012, 24: 628-634. · DOI · Paper page
  18. Morales MG, Cabrera D, Cespedes C, Vio CP, Vazquez Y, Brandan E, Cabello-Verrugio C: Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2). Cell Tissue Res. 2013, 353: 173-187. · DOI
  19. Dangain J, Vrbova G: Muscle development in mdx mutant mice. Muscle Nerve. 1984, 7: 700-704. · DOI · Paper page
  20. De Luca A, Pierno S, Liantonio A, Cetrone M, Camerino C, Fraysse B, Mirabella M, Servidei S, Ruegg UT, Conte Camerino D: Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J Pharm Exp Thera. 2003, 304: 453-463. · DOI · Paper page
  21. Morales MG, Gutierrez J, Cabello-Verrugio C, Cabrera D, Lipson KE, Goldschmeding R, Brandan E: Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy. Hum Mol Gen. 2013, 22: 4938-4951. · DOI · Paper page
  22. Suelves M, Lopez-Alemany R, Lluis F, Aniorte G, Serrano E, Parra M, Carmeliet P, Munoz-Canoves P: Plasmin activity is required for myogenesis in vitro and skeletal muscle regeneration in vivo. Blood. 2002, 99: 2835-2844. · DOI · Paper page
  23. Suelves M, Vidal B, Serrano AL, Tjwa M, Roma J, Lopez-Alemany R, Luttun A, de Lagran MM, Diaz-Ramos A, Jardi M, Roig M, Dierssen M, Dewerchin M, Carmeliet P, Muñoz-Cánoves P: uPA deficiency exacerbates muscular dystrophy in MDX mice. J Cell Biol. 2007, 178: 1039-1051. · DOI · Paper page
  24. Carlson BM, Billington L, Faulkner J: Studies on the regenerative recovery of long-term denervated muscle in rats. Rest Neurol Neurosci. 1996, 10: 77-84.
  25. Gargioli C, Coletta M, De Grandis F, Cannata SM, Cossu G: PlGF-MMP-9-expressing cells restore microcirculation and efficacy of cell therapy in aged dystrophic muscle. Nat Med. 2008, 14: 973-978. · DOI
  26. Muir LA, Chamberlain JS: Emerging strategies for cell and gene therapy of the muscular dystrophies. Expert Rev Mol Med. 2009, 11: e18- · DOI · Paper page
  27. Turgeman T, Hagai Y, Huebner K, Jassal DS, Anderson JE, Genin O, Nagler A, Halevy O, Pines M: Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone. Neuro Dis. 2008, 18: 857-868. · DOI
  28. Alexakis C, Partridge T, Bou-Gharios G: Implication of the satellite cell in dystrophic muscle fibrosis: a self-perpetuating mechanism of collagen overproduction. Am J Physiol Cell Physiol. 2007, 293: C661-C669. · DOI · Paper page
  29. Morrison J, Palmer DB, Cobbold S, Partridge T, Bou-Gharios G: Effects of T-lymphocyte depletion on muscle fibrosis in the mdx mouse. Am J Pathol. 2005, 166: 1701-1710. · DOI
  30. Vidal B, Serrano AL, Tjwa M, Suelves M, Ardite E, De Mori R, Baeza-Raja B, Martinez de Lagran M, Lafuste P, Ruiz-Bonilla V, Jardí M, Gherardi R, Christov C, Dierssen M, Carmeliet P, Degen JL, Dewerchin M, Muñoz-Cánoves P: Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev. 2008, 22: 1747-1752. · DOI · Paper page
  31. Vidal B, Ardite E, Suelves M, Ruiz-Bonilla V, Janue A, Flick MJ, Degen JL, Serrano AL, Munoz-Canoves P: Amelioration of Duchenne muscular dystrophy in mdx mice by elimination of matrix-associated fibrin-driven inflammation coupled to the alphaMbeta2 leukocyte integrin receptor. Hum Mol Gen. 2012, 21: 1989-2004. · DOI · Paper page
  32. Kharraz Y, Guerra J, Mann CJ, Serrano AL, Munoz-Canoves P: Macrophage plasticity and the role of inflammation in skeletal muscle repair. Mediators Inflam. 2013, 2013: 491497- · DOI · Paper page
  33. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich JM, Sladky JT, Kelly AM: The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature. 1991, 352: 536-539. · DOI · Paper page
  34. Chandrasekharan K, Yoon JH, Xu Y, deVries S, Camboni M, Janssen PM, Varki A, Martin PT: A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophy. Sci Trans Med. 2010, 2: 42ra54- · DOI · Paper page
  35. Wehling-Henricks M, Jordan MC, Gotoh T, Grody WW, Roos KP, Tidball JG: Arginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy. PloS one. 2010, 5: e10763- · DOI · Paper page
  36. Zhou L, Rafael-Fortney JA, Huang P, Zhao XS, Cheng G, Zhou X, Kaminski HJ, Liu L, Ransohoff RM: Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice. J Neurol Sci. 2008, 264: 106-111. · DOI
  37. Desguerre I, Arnold L, Vignaud A, Cuvellier S, Yacoub-Youssef H, Gherardi RK, Chelly J, Chretien F, Mounier R, Ferry A, Chazaud B: A new model of experimental fibrosis in hindlimb skeletal muscle of adult mdx mouse mimicking muscular dystrophy. Muscle Nerve. 2012, 45: 803-814. · DOI
  38. Bernasconi P, Di Blasi C, Mora M, Morandi L, Galbiati S, Confalonieri P, Cornelio F, Mantegazza R: Transforming growth factor-beta1 and fibrosis in congenital muscular dystrophies. Neuromusc Dis. 1999, 9: 28-33. · DOI

Cited by

See all 100

Metadata

Authors
Pessina, P., Cabrera, D., Morales, M. G., Riquelme, C. A., Gutiérrez, J., Serrano, A. L., Brandan, E., & Muñoz-Cánoves, P.
Venue
Skeletal Muscle
Published
2014-08-25
Volume
4
Issue
1
Pages
7-7
ISSN
2044-5040 (ISSN-L)
OpenAlex
W2152935078
Cited by
100
References
6
FWCI
3.16
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel and optimized strategies for inducing fibrosis in vivo: focus on Duchenne Muscular Dystrophy. https://app.cochat.ai/papers/10.1186/2044-5040-4-7
The paper
Pessina, P., Cabrera, D., Morales, M. G., Riquelme, C. A., Gutiérrez, J., Serrano, A. L., Brandan, E., & Muñoz-Cánoves, P. (2014). Novel and optimized strategies for inducing fibrosis in vivo: focus on Duchenne Muscular Dystrophy. Skeletal Muscle. https://doi.org/10.1186/2044-5040-4-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.